Clinical Trials · NCT05468632
A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE)
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 314
- Start date
- Jul 2022
- Locations
- 17 sites, North Macedonia
- Primary endpoint
- Change in glycated haemoglobin (HbA1c)